Neuro / ACTH Fragment

Semax

A synthetic ACTH(4-10) analogue examined for neurotrophic and neuroprotective pathways.

Research domain: Neuro
Presentation: 10 mg / vial
Assayed purity: 99.66%
Evidence base: Established

Also designatedACTH(4-10) analogue · N-acetyl semax · Semax acetate

NeuroVerified

Quick facts

Purity specification: ≥ 99% by HPLC
Physical form: Lyophilised powder
Presentation: 10 mg / vial
Evidence base: Established
Intended use: Laboratory research only

Current batch · EVN-SMX-2604

Assayed purity99.66%

98%Spec ≥ 99%100%

Meridian Analytical Laboratories, 15 Apr 2026. Assayed content 9.98 mg / 10 mg.

View certificate

Enquire Now

Research overview

How it is characterised

Semax is a synthetic heptapeptide analogue of the adrenocorticotropic hormone fragment ACTH(4-10), extended with a proline-glycine-proline sequence that confers resistance to enzymatic degradation while removing corticotropic activity. Published work examines its action on brain-derived neurotrophic factor and nerve growth factor expression, and on dopaminergic and serotonergic signalling.

Mechanism

Characterised as raising BDNF and NGF transcript levels in hippocampal and cortical preparations without the adrenocorticotropic activity of the parent fragment. Additional work examines effects on the dopaminergic and serotonergic systems and on markers of cerebral perfusion in ischaemia models.

Applications

Neurotrophic factor research
Central nervous system model studies
Peptide stability profiling
Comparative regulatory peptide investigation

Research focus

Areas of published investigation

The following describe where this compound has been examined in the scientific literature. They are not claims of effect, and nothing here should be read as a therapeutic indication.

01BDNF and NGF expression

02Dopaminergic and serotonergic signalling

03Neuroprotective pathway characterisation

04Cerebral perfusion models

Research compatibility

Frequently co-studied

Compounds that appear alongside Semax in the published record, and the reason the literature examines them together.

Included in research stacks

Cognitive Protocol

Molecular & pharmacokinetic data

The physical record

Verify every figure against the certificate of analysis for the batch you hold. Where the label and the assay disagree, the assay is the number to calculate from.

CAS number: 80714-61-0
Molecular formula: C₃₇H₅₁N₉O₁₀S
Molar mass: ≈ 813.93 g/mol
Sequence: MEHFPGP
Reported half-life: Extended relative to the parent ACTH fragment
Solubility: Readily soluble in water

Analytical record

Batch EVN-SMX-2604

Analysed by Meridian Analytical Laboratories, ISO/IEC 17025 accredited, under accession MAL-26-04355. The certificate is retrievable from the issuing laboratory independently of us.

Full certificate

Retention time (min)RP-HPLC · UV 214 nm

Purity: 99.66%RP-HPLC, UV 214 nm · spec ≥ 99.0%
Identity: 813.8 Da (theoretical 813.9)ESI-MS · spec Conforms to theoretical mass
Assayed content: 99.8% of labelRP-HPLC against reference standard · spec 95.0 – 110.0% of label
Water content: 2.9%Karl Fischer titration · spec ≤ 8.0%
Residual solvents: Acetonitrile 66 ppm; TFA below quantitationHeadspace GC-FID · spec Within USP <467> limits
Appearance: White lyophilised cakeVisual inspection · spec Conforms

Storage

Store lyophilised at −20 °C, protected from light and moisture. Following reconstitution, hold at 2–8 °C and use within the interval stated on the batch certificate of analysis.

Handling

Allow the vial to reach ambient temperature before breaking the seal so atmospheric moisture does not condense onto the cake. Introduce diluent slowly against the vial wall rather than directly onto the powder, and swirl rather than shake. Avoid repeated freeze-thaw cycles; aliquot where a preparation will be drawn on more than once.